[Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru].

OBJECTIVE To describe clinical and biological characteristics of subjects with virologic failure who participated in the sexually transmitted diseases HIV/AIDS National Program from a Peruvian public hospital. MATERIALS AND METHODS An exploratory descriptive study was performed with data from subjects older than 18 who started high activity antiretroviral therapy (HAART) between May 2004 and December 2009 and who had a viral load control after 24 weeks of HAART. Virologic failure was defined as a viral load value above 1000 copies/mL on follow up after 24 weeks on HAART. RESULTS Of 1478 records of patients on HAART analyzed, the median age was 35 years [IQR, 29-41] and 69.6% were male. Also, virologic failure occurred in 24% and 3.7% died. Of subjects with virologic failure, 9.5% died. On multivariate analysis, age, history of antiretroviral use before starting HAART, change of antiretroviral therapy due to toxicity, opportunistic infections during HAART, level of CD4 + lymphocytes below 100 cells/ml at start of HAART, adherence and clinical stage were independently associated with virologic failure. In the group of patient with no history of antiretroviral use before starting HAART, age, opportunistic infections during HAART were associated with virologic failure. CONCLUSION This study identified factors associated with virologic failure. Further studies are needed to evaluate whether the use of these factors can help to identify prospectively patients at high risk of failure, and to design interventions aimed to reduce this risk.

[1]  C. Leen,et al.  7.0 Managing virological failure , 2012, HIV medicine.

[2]  E. Ticona,et al.  Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru. , 2012, AIDS research and human retroviruses.

[3]  Markus Sköld,et al.  Tuberculosis and HIV Co-Infection , 2012, PLoS pathogens.

[4]  C. Leen,et al.  Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study , 2011, HIV medicine.

[5]  O. Kirk,et al.  Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam , 2011, International journal of STD & AIDS.

[6]  C. Goujard,et al.  Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment. , 2011, AIDS research and human retroviruses.

[7]  Alejandro Afani S,et al.  [Antiretroviral resistance in human immunodeficiency virus infection]. , 2011, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[8]  L. Mofenson,et al.  Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  B. Shepherd,et al.  Long-Term Outcomes of a National Expanded Access Program to Antiretroviral Therapy: The Chilean AIDS Cohort , 2010, Journal of acquired immune deficiency syndromes.

[10]  B. Lau,et al.  Virologic and immunologic response to HAART, by age and regimen class , 2010, AIDS.

[11]  D. Masys,et al.  Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America , 2010, PloS one.

[12]  C. Diazgranados,et al.  Antiretroviral drug resistance in HIV-infected patients in Colombia. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  Yuchiao Chang,et al.  Predicting virologic failure in an HIV clinic. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  S. Rosen,et al.  Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review , 2009, AIDS care.

[15]  J. Bartlett,et al.  Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. , 2009, The Lancet. Infectious diseases.

[16]  J. V. van Oosterhout,et al.  Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria , 2009, Tropical medicine & international health : TM & IH.

[17]  S. Kiertiburanakul,et al.  Emerging of HIV drug resistance: epidemiology, diagnosis, treatment and prevention. , 2009, Current HIV research.

[18]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[19]  C. Diazgranados,et al.  Rate and predictors of optimal virologic response to antiretroviral therapy in Colombia. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[20]  D. Klein,et al.  Older age and the response to and tolerability of antiretroviral therapy. , 2007, Archives of internal medicine.

[21]  M. I. A. Montoya,et al.  Factores asociados con el resultado virológico de la Terapia Antirretroviral Altamente Activa (HAART) en 340 pacientes naive, Medellín-Colombia, 1997-2000 , 2007 .

[22]  R. Grant,et al.  Linking HIV and Antiretroviral Drug Resistance Surveillance in Peru: A Model for a Third-Generation HIV Sentinel Surveillance , 2006, Journal of acquired immune deficiency syndromes.

[23]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[24]  F. Oort,et al.  Self-Reported Adherence to Antiretroviral Therapy for HIV-1 Infection and Virologic Treatment Response: A Meta-Analysis , 2005, Journal of acquired immune deficiency syndromes.

[25]  C. Hinkin,et al.  Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse , 2004, AIDS.

[26]  B. Hoen,et al.  [Predictive factors of virological response to primary antiretroviral treatment]. , 2004, Presse medicale.

[27]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[28]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.